Opthea Ltd has released a press release.
Appendix 4E and Annual Report 2016
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Opthea
- Opthea reports positive data from Phase 1 wet AMD Trial
- Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD
- Opthea Ph1 wAMD Trial with OPT-302 Meets Primary Objective
- Circadian Capital Raising Prospectus
- Opthea Completes Patient Enrolment for Phase 1 wet AMD Trial
Later from Opthea
- Opthea receives $2.6M R&D tax incentive
- Opthea Completes Patient Enrolment in Ph1/2A wAMD Trial
- Opthea Completes FDA Meeting to Inform OPT-302 Program
- Opthea Receives EU Regulatory Feedback for OPT-302 Program
- Opthea Launches A$45M Financing for Clinical Development
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea